- Rentschler Biopharma new production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA in the U.S. is now fully operational.
Rentschler Biopharma SE has announced the full operational status of its new production line in Milford, Massachusetts. This expansion, the largest in the company’s history, doubles its global capacity to meet the increasing demand for biopharmaceuticals aimed at treating rare and serious diseases.
The new state-of-the-art production line is already handling its first major client project, with several more in the pipeline. Rentschler Biopharma continues to welcome new projects and clients, reinforcing its commitment to supporting innovative therapies.
Benedikt von Braunmühl, CEO of Rentschler Biopharma SE, stated, “The completion of our new, state-of-the-art production line is an important milestone for our company and emphasizes Rentschler Biopharma’s strong capabilities in the U.S. Our clients are our partners, and we are working with them to empower tomorrow’s therapies today.”
Tom Roberts, President of Rentschler Biopharma Inc. and General Manager U.S., added, “Our new line is vital to growing our business and effectively serving the U.S. market. I am excited about bringing in new clients as well as expanding our support of existing ones with a reliability they can trust.”
Overview of outsourcing trends 
